JP Morgan Chase
RLMD icon

JP Morgan Chase’s Relmada Therapeutics RLMD Stock Holding History

JP Morgan Chase’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-92,200
Closed -$3.41M – 6923
2022
Q3 		$3.41M Buy
+92,200
New +$2.55M ﹤0.01% 3047

Other funds holding RLMD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Chase's RLMD Position: Q3 2025 in Review

JP Morgan Chase sold out of Relmada Therapeutics (RLMD) in Q3 2025, closing a stake of 5,103 shares — an estimated $3.06K sold.

JP Morgan Chase first reported a position in RLMD in Q2 2020 and held it in 21 quarters. The position peaked at $1.06M in Q2 2024. 44 funds tracked by Wall St. Rank hold RLMD as of Q3 2025.

  • JP Morgan Chase reported no remaining Relmada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 5,103 Relmada Therapeutics shares in Q3 2025, an estimated $3.06K.
  • JP Morgan Chase first reported a position in Relmada Therapeutics in Q2 2020 and held it in 21 quarters.
  • JP Morgan Chase's Relmada Therapeutics position peaked at $1.06M in Q2 2024.
  • 44 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.